logo
  • Global Challenge
  • Our Approach
  • Partnering
  • Pipeline
  • Join Us
  • News & Events
  • Investors
    • Company Information
    • Board and Management
    • Advisors
    • Investor Alert
  • Publications
  • Contact

World Antibiotic Awareness Week Video

November 18, 2019
|In Alderley Park, News, Publications
|By Carl Curran

 

 

  • Prev
  • All Stories
  • Next

Related News

Interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial

Accelerates plans for Phase IIa study

Press Releases,Breaking News

Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director

Infex Therapeutics is pleased to announce the appointment of Professor Colm Leonard as a…

Press Releases,Breaking News

Antimicrobial discovery and drug development – RSC Podcast

How do we develop drugs like antibiotics? How long does it take for such a drug to go…

Breaking News,Publications

Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation

This designation gives MET-X an accelerated U.S. regulatory pathway and an additional…

Press Releases,Breaking News,Pipeline

Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa

Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the…

Press Releases,Breaking News,Pipeline

Infex Awarded Biomedical Catalyst Grant For COV-X Project

Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a…

Press Releases,Breaking News

COVID-19 Pandemic Triggers Upsurge in MBL Infections

New research has discovered that the ongoing COVID-19 pandemic has triggered a…

Breaking News,Pipeline

CARB-X Receives Additional $370m from U.S. Government and Wellcome

Enables continued investment in innovative projects to tackle the growing global threat…

News,Press Releases

Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients

MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022

News,Press Releases,Pipeline

© Infex Therapeutics Ltd. All rights reserved.